湖南南新制药股份有限公司股票交易严重异常波动公告

Core Points - Hunan Nanxin Pharmaceutical Co., Ltd. has experienced a significant stock price decline, with a cumulative drop of 70% over the last 30 trading days, indicating severe abnormal trading fluctuations [2][4] - The company has confirmed that its daily operations are normal, with no significant changes in market conditions or industry policies, and no undisclosed major events [5][6] - As of October 9, 2025, the company's stock price was 9.10 yuan per share, and the rolling price-to-earnings ratio for the pharmaceutical manufacturing industry was 30.49 times, while the company's P/E ratio is negative due to a loss in audited net profit for 2024 [2][10] Abnormal Trading Situation - The stock price has deviated significantly, with a cumulative drop of 70% over 30 trading days, qualifying as severe abnormal trading according to Shanghai Stock Exchange regulations [4] Company Operations and Major Events - The company conducted a self-examination and confirmed that its daily operations are normal, with no major changes or undisclosed significant matters [5][6] - The company received a notice from the China Securities Regulatory Commission regarding a suspected violation of annual report disclosure laws, leading to an investigation [6] - The company has terminated a major asset restructuring agreement with several other pharmaceutical companies [6] Media and Market Rumors - The company has not identified any recent media reports or public rumors that could significantly impact its stock price [8] Sensitive Information - During the period of severe stock price fluctuations, there were no stock trades by the company's directors, supervisors, senior management, or controlling shareholders [9]